iShares NASDAQ US Biotechnology UCITS ETF (LON:BTEE)

Assets	24.41M
Expense Ratio	0.35%
PE Ratio	17.38
Dividend (ttm)	0.02
Dividend Yield	0.50%
Ex-Dividend Date	Jun 12, 2025
Payout Frequency	Semi-Annual
Payout Ratio	n/a
1-Year Return	-4.86%

Volume	54
Open	6.10
Previous Close	6.18
Day's Range	6.10 - 6.23
52-Week Low	5.22
52-Week High	7.20
Beta	0.78
Holdings	272
Inception Date	Mar 6, 2018

About BTEE

iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sector. The fund invests in the stocks of companies across all market capitalizations. It seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing representative sampling methodology. iShares NASDAQ US Biotechnology UCITS ETF was formed on October 19, 2017 and is domiciled in Ireland.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: London Stock Exchange
• Ticker Symbol: BTEE
• Provider: iShares
• Index Tracked: NASDAQ Biotechnology Index

Performance

BTEE had a total return of -4.86% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.10%.

Top 10 Holdings

46.74% of assets

Name	Symbol	Weight
Gilead Sciences, Inc.	GILD	8.24%
Amgen Inc.	AMGN	8.17%
Vertex Pharmaceuticals Incorporated	VRTX	8.12%
Regeneron Pharmaceuticals, Inc.	REGN	5.93%
AstraZeneca PLC	AZN	4.61%
Alnylam Pharmaceuticals, Inc.	ALNY	4.17%
Biogen Inc.	BIIB	2.05%
argenx SE	ARGX	1.98%
Insmed Incorporated	INSM	1.85%
Royalty Pharma plc	RPRX	1.61%

Dividend History

Ex-Dividend	Amount	Pay Date
Jun 12, 2025	£0.01472	Jun 25, 2025
Dec 12, 2024	£0.0089	Dec 27, 2024
Jun 13, 2024	£0.01372	Jun 26, 2024
Dec 14, 2023	£0.00846	Dec 29, 2023
Jun 15, 2023	£0.01113	Jun 28, 2023
Dec 15, 2022	£0.00851	Dec 30, 2022